-
Foundation Medicine Expands Genomic Profiling Partnership with Sequanta Technologies in China
•
US-based Contract Research Organization (CRO) Foundation Medicine Inc. has announced the expansion of its existing partnership with Chinese firm Sequanta Technologies Co., Ltd, to provide genomic profiling services in support of clinical research and development of oncology therapies in China. Historical Collaboration and Future PlansSince 2014, Foundation Medicine has utilized…
-
Jenscare’s LuX-Valve Plus Completes Compassionate Use Cases in Asia-Pacific
•
Jenscare Scientific Co., Ltd (HKG: 9877), a leading device maker specializing in structural heart disease solutions, has announced the successful completion of a series of paid compassionate use cases for its innovative transjugular tricuspid valve replacement product, LuX-Valve Plus, across multiple hospitals in the Asia-Pacific region. Clinical Success and Industry…
-
Fosun Pharmaceutical to Acquire 14% Stake in UnitedHealthcare for USD 34 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to invest RMB 248.9 million (USD 34 million) in the acquisition of 97.22 million new shares of UnitedHealthcare, securing a 14% stake in the insurance firm. This strategic investment aims to diversify Fosun’s portfolio and enhance its presence in…
-
Skyline Therapeutics Gains NMPA Approval for SKG0106 in Neovascular AMD Treatment
•
Skyline Therapeutics has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative drug SKG0106, an intraocular injection solution for the treatment of neovascular age-related macular degeneration (nAMD). Innovative Gene Therapy MechanismSKG0106 is a recombinant adeno-associated virus (rAAV) gene therapy drug, utilizing…
-
Accuredit Therapeutics Initiates First Dosing of Gene Therapy ART001 for ATTR
•
China-based gene therapy start-up Accuredit Therapeutics (Suzhou) Co., Ltd has announced the first dosing of its investigational drug ART001 in seven subjects with transthyretin amyloidosis (ATTR), as part of an investigator-initiated trial (ITT). The drug candidate has demonstrated good safety and achieved a clinically significant decrease in transthyroxine (TTR) protein…
-
Bayer HealthCare Launches First Innovation Center in Beijing’s ETown
•
Bayer HealthCare (ETR: BAYN) has formally inaugurated its inaugural innovation center in China, strategically situated within the Beijing Economic-Technological Development Area, commonly referred to as Beijing ETown. This marks a significant expansion of the company’s global footprint and commitment to innovation in the Asia-Pacific region. Collaboration and Research FocusThe German…
-
China’s State Council Unveils Plan to Boost Patent Commercialization by 2025
•
China’s State Council has recently approved the “Special Action Plan for Patent Commercialization and Utilization (2023-2025),” outlining ambitious targets for the commercialization of high-value patents in China by 2025. The plan is designed to significantly increase the commercialization rates of patents held by universities and research institutes. Commercialization Targets and…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis Novo Nordisk NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
